-
October 23, 2026
The U.S. Department of Commerce is opening investigations into whether certain chemical compounds imported from China are being sold at less than fair value and are subsidized, the department said Friday.
-
October 22, 2026
Nestle was hit with a proposed false advertising class action Wednesday in New Jersey federal court alleging its Solgar VM-75 supplements contain dangerous levels of vitamin B6, which can heighten the risk of developing peripheral neuropathy or worsen the condition.
-
October 22, 2026
The coalition fighting marijuana legalization won a partial victory after a Drug Enforcement Administration's administrative law judge on Thursday allowed into the record a U.S. Government Accountability Office report the group championed but denied new testimony on it, saying the report "speaks for itself."
-
October 22, 2026
The Texas Office of the Attorney General on Thursday announced that pharmaceutical company Gilead Sciences Inc. signed off on a $45 million settlement to end claims that the company ran an illegal kickback scheme in order to get prescribers to favor its medications.
-
October 22, 2026
An indoor air quality company failed to prove academic publisher Elsevier acted with malice in printing an article questioning the effectiveness of its air purification technology sufficient to sustain a claim for defamation, a North Carolina federal judge ruled Thursday.
-
October 22, 2026
The full Ninth Circuit declined to reconsider an appellate panel's recent decision reviving a surgical repair company's antitrust suit alleging Intuitive Surgical blocked third parties from supplying parts for its popular da Vinci surgery robot, according to an order issued Thursday.
-
October 22, 2026
Johnson & Johnson told the Third Circuit Thursday that the U.S. Supreme Court's recent decision not to take up a group of executives' federal benefits dispute backed its position in an appeal from J&J workers who alleged their health plans were saddled with excessive prescription drug fees.
-
October 22, 2026
Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for $8 million.
-
October 22, 2026
The Purdue Pharma bankruptcy trust and trustees for some members of the Sackler family have filed separate documents in a New York bankruptcy court challenging moves they described as continued attempts by Richard S. Sackler and his wife, Lin Gao, to block parts of the drugmaker's bankruptcy plan.
-
October 22, 2026
10x Genomics has told a Delaware federal judge it will no longer pursue a patent case against Parse Biosciences Inc. over methods of analyzing genetic information, a move following the Federal Circuit's refusal to revive the remaining three patents-at-issue.
-
October 22, 2026
The Federal Trade Commission has requested additional information about Curium's planned $8 billion acquisition of fellow radiopharmaceutical company Lantheus Holdings Inc., extending a waiting period that prevents the transaction from closing.
-
October 22, 2026
The Patent Trial and Appeal Board has invalidated claims in an Inari Medical Inc. patent on valves used in surgery to prevent blood loss, handing another win to challenger Imperative Care as it fends off an infringement lawsuit in California.
-
October 22, 2026
DLA Piper has hired a former Shook Hardy & Bacon LLP product liability partner in San Francisco who has decades of experience defending companies in high-stakes disputes involving hundreds of millions of dollars.
-
October 21, 2026
A long list of firms — including Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP — are steering Sweden-based EQT Private Equity's $12.1 billion takeover of life sciences testing company Qiagen NV, according to a Wednesday announcement.
-
October 21, 2026
Reckitt Benckiser urged a New Jersey federal judge to end a former senior regulatory manager's suit alleging she was fired for raising product safety issues, arguing Tuesday she rejected a lateral transfer amid a global reorganization and unsuccessfully gambled the company would give in to her promotion and higher pay demands.
-
October 21, 2026
An Illinois federal judge seemed hesitant Wednesday to halt a state law barring drugmakers from trying to impose restrictions on pharmacies under contract with a federal drug pricing discount program, saying the state seems to be maximizing public health in an area the statute doesn't address.
-
October 21, 2026
Intuitive Surgical said in its quarterly earnings report Tuesday that it reached a $450 million settlement to resolve a hospital class action alleging it monopolized the market for servicing its da Vinci surgical robots, subject to approval by a California federal judge.
-
October 21, 2026
Amarin Pharma Inc. is dropping its patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, months after the U.S. Supreme Court shut the case down.
-
October 21, 2026
Squire Patton Boggs LLP announced Wednesday that it has added the co-chair of Akerman LLP's public finance group to bolster its capacity to handle public finance, healthcare finance and other matters.
-
October 21, 2026
The U.S. Supreme Court on Wednesday allowed federal prisons to continue to offer gender transition medical services to incarcerated people.
-
October 20, 2026
A New York federal judge has dismissed a proposed shareholder class action alleging medical device maker Integer Holdings Corp. hid plummeting demand for cardiac devices and misled investors about its overall growth, concluding that the allegations do not suggest its disclosures in 2024 and 2025 were untrue or deceptive.
-
October 20, 2026
In his latest round of decisions, U.S. Patent and Trademark Office Director John Squires has granted 10 petitions seeking review of patents and denied two others, both on discretionary grounds.
-
October 20, 2026
Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of their prescription allergy drug Xolair amounts to patent infringement.
-
October 20, 2026
Investors in the now-defunct biotechnology company Zymergen received final approval of their $125 million deal ending claims that the company misled shareholders ahead of its initial public offering, while plaintiffs' attorneys also had their fee request approved.
-
October 20, 2026
A Second Circuit panel affirmed a lower court's decision Tuesday, refusing to block Connecticut from enforcing a cap on generic and off-patent drug prices while a trade association for drug wholesalers challenges the statute.